StockData
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. (SRPT) stock

SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.77−0.36 (-2.38%)

Close on Nov 17, 2026Market cap $1.56BP/E –Yield –

Sarepta Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Sarepta Therapeutics's price to sales ratio was 0.9× on Nov 11, 2026, against 0.9× a year earlier. Over the last 5 years it ranged from 0.7× to 13.0×, with a median of 8.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.9×−0.0
2025Dec 31, 20250.9×−6.1
2024Dec 31, 20247.1×−1.1
2023Dec 29, 20238.2×−4.8
2022Dec 30, 202213.0×+1.8
2021Dec 31, 202111.2×−16.0
2020Dec 31, 202027.1×+0.8
2019Dec 31, 201926.3×−0.2
2018Dec 31, 201826.6×−8.4
2017Dec 29, 201735.0×–

More Sarepta Therapeutics figures

See a number that looks wrong?